Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
The US announced a phased tariff schedule on imported generic drugs: zero tariff for two years starting August 1, 2026, rising to 100% for a further one year, and 200% thereafter
The plan is intended to incentivize pharmaceutical manufacturers to build production plants inside the United States within the initial tariff-free window
Industry bodies cautioned that such steep tariffs on generics, if eventually applied, would raise medicine costs for American patients, since generics account for the vast majority of prescriptions filled in the US
The generic-drug tariff plan is separate from an earlier Section 232 "national security" tariff of 100% on patented (branded) pharmaceuticals and active pharmaceutical ingredients (APIs), which industry groups said does not apply to generics
India, the largest single supplier of generic medicines to the US market, is closely watched as the country most exposed to any eventual escalation
Section 232 of the Trade Expansion Act, 1962 — National Security Tariffs on Pharmaceuticals
Section 232 permits the US President to impose tariffs on imports found to threaten national security, based on a Commerce Department investigation. In April 2026, the administration announced a 100% Section 232 tariff on patented pharmaceuticals and associated APIs (effective July 31, 2026), citing US dependence on foreign-made drugs and drug ingredients as a national-security vulnerability. This is legally and functionally distinct from the phased generic-drug tariff, which was announced through separate executive statements rather than a completed Section 232 process.
Key Details
- Section 232 investigation into pharmaceutical imports was initiated by the US Commerce Department in April 2025
- Approximately 53% of patented drugs and 85% of patented APIs sold in the US are estimated to be manufactured abroad
- The Section 232 tariff on patented drugs/APIs is tiered by country — for example, lower rates apply to the UK (10%) than to the EU, Japan, and South Korea (15%)
- The generic-drug schedule (0% for two years, 100% for one year, 200% thereafter starting August 2026) targets reshoring of generic manufacturing specifically, distinct from the patented-drug Section 232 action
The two tariff tracks — Section 232 on patented drugs and the phased generic-drug schedule — together apply pressure across the entire US pharmaceutical import base, but generics (India's core export category) face a longer runway before duties bite.
India's Position as the "Pharmacy of the World" and API Dependency
India is the largest supplier of generic medicines to the United States, supplying an estimated 42-47% of US generic prescriptions by volume (though a smaller ~30% share by value, since Indian generics are typically priced far below branded equivalents). India exported roughly $25.8 billion of pharmaceuticals globally in FY2025, of which about $9.7 billion (nearly 38%) went to the US, its single largest pharmaceutical export market. India, in turn, depends heavily on imported active pharmaceutical ingredients (APIs), historically importing a large share of bulk drugs from China.
Key Details
- India supplies an estimated 42-47% of US generic prescriptions by volume, but a much smaller share (~30%) by value
- India's global pharmaceutical exports (FY2025): approximately $25.8 billion; exports to the US: approximately $9.7 billion (~38%)
- India's Production Linked Incentive (PLI) Scheme for pharmaceuticals (₹6,940 crore, launched 2020) targets 53 critical APIs/key starting materials to cut import dependence, aiming to reduce China-sourced API dependence from around 70% toward below 40%
- The Bulk Drug Parks Scheme (2020) supports three mega API manufacturing parks (Himachal Pradesh, Gujarat, Andhra Pradesh), each with a ₹1,000 crore outlay, to build domestic API capacity
A steep future US tariff on generics would strike directly at India's largest pharmaceutical export market, even as India itself works to reduce its own upstream API dependence through PLI and bulk-drug-park incentives.
WTO TRIPS Agreement and the Generics-versus-Patented Drugs Distinction
The WTO's Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement (1995) sets minimum patent-protection standards, including a 20-year patent term for pharmaceuticals, but permits flexibilities such as compulsory licensing, affirmed and clarified by the Doha Declaration on TRIPS and Public Health (2001). Generic drugs are versions of medicines manufactured after the original patent expires, and are chemically identical, low-cost substitutes for branded drugs — the reason they dominate prescription volumes even though patented drugs dominate revenue.
Key Details
- TRIPS Agreement (1995) mandates a minimum 20-year patent term for pharmaceutical inventions among WTO members
- The Doha Declaration (2001) affirmed members' right to use compulsory licensing and parallel importation to protect public health
- India's Patents Act, 1970 (as amended in 2005 to comply with TRIPS) includes Section 3(d), which restricts patenting of new forms of known substances absent enhanced therapeutic efficacy — a provision central to India's generics-manufacturing capability
- Generic drugs require regulatory bioequivalence approval (in the US, via the FDA's Abbreviated New Drug Application, or ANDA, pathway) rather than fresh clinical trials
India's generics industry exists precisely because of the patent-expiry and compulsory-licensing flexibilities within the global IP framework; a punitive tariff regime on generics would raise costs in a market segment built on affordable, off-patent medicine production.
- Generic drug tariff schedule: 0% from August 1, 2026 (two years) → 100% for one year (from around August 2028) → 200% thereafter (from around August 2029)
- Separate Section 232 tariff on patented drugs/APIs: 100%, effective July 31, 2026 (tiered by country of origin)
- India's share of US generic prescriptions by volume: approximately 42-47%; by value: approximately 30%
- India's pharmaceutical exports to the US (FY2025): approximately $9.7 billion, out of ~$25.8 billion in global pharma exports
- India's PLI Scheme for pharmaceuticals: ₹6,940 crore, covering 53 critical APIs, launched 2020
- TRIPS Agreement minimum pharmaceutical patent term: 20 years